Microdosimetry for Targeted Alpha Therapy of Cancer
Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limit...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Computational and Mathematical Methods in Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/153212 |
id |
doaj-eb5758835e0c4d4a995c1c279cf5430d |
---|---|
record_format |
Article |
spelling |
doaj-eb5758835e0c4d4a995c1c279cf5430d2020-11-25T00:03:08ZengHindawi LimitedComputational and Mathematical Methods in Medicine1748-670X1748-67182012-01-01201210.1155/2012/153212153212Microdosimetry for Targeted Alpha Therapy of CancerChen-Yu Huang0Susanna Guatelli1Bradley M. Oborn2Barry J. Allen3Centre for Experimental Radiation Oncology, St. George Clinical School, University of New South Wales, Kogarah, NSW 2217, AustraliaIllawarra Cancer Care Centre, Wollongong, NSW 2522, AustraliaIllawarra Cancer Care Centre, Wollongong, NSW 2522, AustraliaIngham Institute of Applied Medical Research, Faculty of Medicine, University of Western Sydney, Liverpool, NSW 2170, AustraliaTargeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limited toxicity. However, the dosimetry for the labeled alpha particle is challenging because of the heterogeneous antigen expression among cancer cells and the nature of short-range, high-LET alpha radiation. This paper demonstrates that it is inappropriate to investigate the therapeutic efficacy of TAT by macrodosimetry. The objective of this work is to review the microdosimetry of TAT as a function of the cell geometry, source-target configuration, cell sensitivity, and biological factors. A detailed knowledge of each of these parameters is required for accurate microdosimetric calculations.http://dx.doi.org/10.1155/2012/153212 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chen-Yu Huang Susanna Guatelli Bradley M. Oborn Barry J. Allen |
spellingShingle |
Chen-Yu Huang Susanna Guatelli Bradley M. Oborn Barry J. Allen Microdosimetry for Targeted Alpha Therapy of Cancer Computational and Mathematical Methods in Medicine |
author_facet |
Chen-Yu Huang Susanna Guatelli Bradley M. Oborn Barry J. Allen |
author_sort |
Chen-Yu Huang |
title |
Microdosimetry for Targeted Alpha Therapy of Cancer |
title_short |
Microdosimetry for Targeted Alpha Therapy of Cancer |
title_full |
Microdosimetry for Targeted Alpha Therapy of Cancer |
title_fullStr |
Microdosimetry for Targeted Alpha Therapy of Cancer |
title_full_unstemmed |
Microdosimetry for Targeted Alpha Therapy of Cancer |
title_sort |
microdosimetry for targeted alpha therapy of cancer |
publisher |
Hindawi Limited |
series |
Computational and Mathematical Methods in Medicine |
issn |
1748-670X 1748-6718 |
publishDate |
2012-01-01 |
description |
Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limited toxicity. However, the dosimetry for the labeled alpha particle is challenging because of the heterogeneous antigen expression among cancer cells and the nature of short-range, high-LET alpha radiation. This paper demonstrates that it is inappropriate to investigate the therapeutic efficacy of TAT by macrodosimetry. The objective of this work is to review the microdosimetry of TAT as a function of the cell geometry, source-target configuration, cell sensitivity, and biological factors. A detailed knowledge of each of these parameters is required for accurate microdosimetric calculations. |
url |
http://dx.doi.org/10.1155/2012/153212 |
work_keys_str_mv |
AT chenyuhuang microdosimetryfortargetedalphatherapyofcancer AT susannaguatelli microdosimetryfortargetedalphatherapyofcancer AT bradleymoborn microdosimetryfortargetedalphatherapyofcancer AT barryjallen microdosimetryfortargetedalphatherapyofcancer |
_version_ |
1725434855500546048 |